Gabapentin 50 MG/ML Oral Solution — RxCUI 283523
RxNorm drug concept · Semantic clinical drug
RxCUI 283523
Semantic clinical drug · SCD
● Current RxNorm concept 28 FDA products
36 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI283523
Official nameGabapentin 50 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asgabapentin 250 MG per 5 ML Oral Solution; gabapentin 250 MG in 5 mL Oral Solution; gabapentin 300 MG per 6 ML Oral Solution; gabapentin 500 MG per 10 ML Oral Solution
FDA products mapped28
Package NDCs mapped36
Reported Medicaid activity (SDUD)151,731 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Gabapentin: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It's used for nerve pain after shingles (postherpetic neuralgia). Many gabapentin products are also used as add-on treatment for partial seizures in epilepsy. Horizant is also used...
- Dizziness and sleepiness are the most common side effects. Don't drive or use heavy machinery until you know how it affects you, because you may not judge your own impairment well.
- Talk to your prescriber first. Stopping seizure medicines suddenly can increase seizures. Gralise should be changed or stopped gradually over at least a week.
- Tell me about any opioid or sedating medicine, because together they can slow breathing dangerously. If you use an antacid like Maalox, take gabapentin at least 2 hours after it.
🕸️ Concept Web — How Gabapentin 50 MG/ML Oral Solution Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Gabapentin 50 MG/ML Oral Solution
RxCUI 283523 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Gabapentin
25480IN
-
Gabapentin
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Neurontin
196498BN
-
Neurontin
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Gabapentin Oral Solution
378101SCDF -
Gabapentin Oral Liquid Product
1156680SCDG -
Gabapentin Oral Product
1156681SCDG -
Gabapentin Oral Solution [Neurontin]
364901SBDF -
Neurontin Oral Liquid Product
1182284SBDG -
Neurontin Oral Product
1182285SBDG -
Oral Solution
316968DF -
Oral Liquid Product
1151137DFG - +1 more in this family
-
Gabapentin Oral Solution
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Gabapentin 50 MG/ML
346365SCDC -
Gabapentin 50 MG/ML Oral Solution [Neurontin]
351973SBD -
Gabapentin 50 MG/ML [Neurontin]
575724SBDC
-
Gabapentin 50 MG/ML
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Gabapentin 50 MG/ML
SCDC · 346365 -
Gabapentin Oral Solution
SCDF · 378101 -
Gabapentin Oral Liquid Product
SCDG · 1156680 -
Gabapentin Oral Product
SCDG · 1156681
Brand-Name Concepts
-
Gabapentin 50 MG/ML Oral Solution [Neurontin]
SBD · 351973 -
Gabapentin 50 MG/ML [Neurontin]
SBDC · 575724 -
Gabapentin Oral Solution [Neurontin]
SBDF · 364901 -
Neurontin Oral Liquid Product
SBDG · 1182284 -
Neurontin Oral Product
SBDG · 1182285 -
Neurontin
BN · 196498
📦 FDA Products & Package NDCs
28 products · 36 package NDCs
36 package NDCs map to RxCUI 283523 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00071-0401-24 | 100 TABLET, FILM COATED in 1 BOTTLE (0071-0401-24) | Neurontin | Parke-Davis Div of Pfizer Inc | 1998-10-09 |
| 00071-0803-24 | 100 CAPSULE in 1 BOTTLE (0071-0803-24) | Neurontin | Parke-Davis Div of Pfizer Inc | 1993-12-30 |
| 00071-0805-24 | 100 CAPSULE in 1 BOTTLE (0071-0805-24) | Neurontin | Parke-Davis Div of Pfizer Inc | 1993-12-30 |
| 00071-0806-24 | 100 CAPSULE in 1 BOTTLE (0071-0806-24) | Neurontin | Parke-Davis Div of Pfizer Inc | 1993-12-30 |
| 00071-2012-47 | 1 BOTTLE, PLASTIC in 1 CARTON (0071-2012-47) / 470 mL in 1... | Neurontin | Parke-Davis Div of Pfizer Inc | 2022-07-12 |
| 00121-1067-16 | 470 mL in 1 BOTTLE, PLASTIC (0121-1067-16) | Gabapentin | PAI Holdings, LLC dba PAI Pharma | 2025-06-12 |
| 00121-2134-40 | 4 TRAY in 1 CASE (0121-2134-40) / 10 CUP, UNIT-DOSE in 1 TR... | Gabapentin | PAI Holdings, LLC dba PAI Pharma | 2025-06-12 |
| 00121-4067-40 | 4 TRAY in 1 CASE (0121-4067-40) / 10 CUP, UNIT-DOSE in 1 TR... | Gabapentin | PAI Holdings, LLC dba PAI Pharma | 2025-06-12 |
| 17856-0600-01 | 72 CUP, UNIT-DOSE in 1 BOX (17856-0600-1) / 5 mL in 1 CUP,... | Gabapentin | ATLANTIC BIOLOGICALS CORP. | 2024-05-07 |
| 17856-0600-02 | 72 CUP, UNIT-DOSE in 1 BOX (17856-0600-2) / 6 mL in 1 CUP,... | Gabapentin | ATLANTIC BIOLOGICALS CORP. | 2024-05-07 |
| 17856-0600-07 | 5 BOX, UNIT-DOSE in 1 SYRINGE (17856-0600-7) / 120 SYRINGE... | Gabapentin | ATLANTIC BIOLOGICALS CORP. | 2024-05-07 |
| 17856-0600-08 | 60 SYRINGE in 1 BOX, UNIT-DOSE (17856-0600-8) / 2 mL in 1 S... | Gabapentin | ATLANTIC BIOLOGICALS CORP. | 2025-02-05 |
| 31722-0069-47 | 1 BOTTLE in 1 CARTON (31722-069-47) / 470 mL in 1 BOTTLE | GABAPENTIN | Camber Pharmaceuticals, Inc. | 2024-01-17 |
| 42192-0608-05 | 5 mL in 1 CUP, UNIT-DOSE (42192-608-05) | Gabapentin | Acella Pharmaceuticals, LLC | 2019-08-16 |
| 42192-0608-06 | 6 mL in 1 CUP, UNIT-DOSE (42192-608-06) | Gabapentin | Acella Pharmaceuticals, LLC | 2019-08-16 |
| 42192-0608-16 | 470 mL in 1 BOTTLE (42192-608-16) | Gabapentin | Acella Pharmaceuticals, LLC | 2012-10-01 |
| 42192-0608-40 | 40 CUP, UNIT-DOSE in 1 BOX (42192-608-40) / 6 mL in 1 CUP,... | Gabapentin | Acella Pharmaceuticals, LLC | 2019-08-16 |
| 42192-0608-45 | 40 CUP, UNIT-DOSE in 1 BOX (42192-608-45) / 5 mL in 1 CUP,... | Gabapentin | Acella Pharmaceuticals, LLC | 2021-05-05 |
| 44523-0120-16 | 470 mL in 1 BOTTLE (44523-120-16) | Gabapentin | BioComp Pharma, Inc. | 2023-11-30 |
| 58151-0281-01 | 100 CAPSULE in 1 BOTTLE (58151-281-01) | Neurontin | Viatris Specialty LLC | 2025-07-10 |
| 58151-0282-01 | 100 CAPSULE in 1 BOTTLE (58151-282-01) | Neurontin | Viatris Specialty LLC | 2026-04-09 |
| 58151-0283-01 | 100 CAPSULE in 1 BOTTLE (58151-283-01) | Neurontin | Viatris Specialty LLC | 2025-10-01 |
| 58151-0284-01 | 100 TABLET, FILM COATED in 1 BOTTLE (58151-284-01) | Neurontin | Viatris Specialty LLC | 2025-10-01 |
| 58151-0285-01 | 100 TABLET, FILM COATED in 1 BOTTLE (58151-285-01) | Neurontin | Viatris Specialty LLC | 2025-09-19 |
| 58151-0290-35 | 1 BOTTLE in 1 CARTON (58151-290-35) / 470 mL in 1 BOTTLE | Neurontin | Viatris Specialty LLC | 2026-01-14 |
| 60687-0919-87 | 4 TRAY in 1 CASE (60687-919-87) / 10 CUP, UNIT-DOSE in 1 TR... | Gabapentin | American Health Packaging | 2026-03-02 |
| 65162-0698-54 | 50 CUP, UNIT-DOSE in 1 CARTON (65162-698-54) / 5 mL in 1 CU... | Gabapentin | Amneal Pharmaceuticals LLC | 2011-09-30 |
| 65162-0698-90 | 473 mL in 1 BOTTLE (65162-698-90) | Gabapentin | Amneal Pharmaceuticals LLC | 2011-09-30 |
| 70518-4445-00 | 10 CUP in 1 BOX (70518-4445-0) / 10 mL in 1 CUP (70518-4445... | Gabapentin | REMEDYREPACK INC. | 2025-08-16 |
| 72162-1318-04 | 470 mL in 1 BOTTLE (72162-1318-4) | Gabapentin | Bryant Ranch Prepack | 2024-11-01 |
| 72888-0104-25 | 470 mL in 1 BOTTLE (72888-104-25) | Gabapentin | Advagen Pharma Ltd | 2023-06-12 |
| 81033-0123-16 | 473 mL in 1 BOTTLE (81033-123-16) | Gabapentin | Kesin Pharma Corporation | 2025-09-01 |
| 81033-0123-44 | 40 CUP, UNIT-DOSE in 1 CARTON (81033-123-44) / 5 mL in 1 CU... | Gabapentin | Kesin Pharma Corporation | 2025-09-01 |
| 81033-0124-44 | 40 CUP, UNIT-DOSE in 1 CARTON (81033-124-44) / 6 mL in 1 CU... | Gabapentin | Kesin Pharma Corporation | 2025-09-01 |
| 82983-0423-47 | 473 mL in 1 BOTTLE (82983-423-47) | Gabapentin | Ajenat Pharmaceuticals LLC | 2025-08-06 |
| 86211-0112-01 | 473 mL in 1 BOTTLE (86211-112-01) | Gabapentin | JVET PHARMACEUTICALS LLC | 2025-12-15 |
Observed labelers:
Viatris Specialty LLC (6) ·
Acella Pharmaceuticals, LLC (5) ·
Parke-Davis Div of Pfizer Inc (5) ·
ATLANTIC BIOLOGICALS CORP. (4) ·
Kesin Pharma Corporation (3) ·
PAI Holdings, LLC dba PAI Pharma (3)
· +9 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.